PDCD1 and non-small cell lung carcinoma: Although ICIs targeting the programmed cell death-1 (PD-1) and PD-ligand (L)-1 pathways improved outcomes compared to cytotoxic chemotherapy, a long-term survival benefit is limited to less than 30% of patients with advanced NSCLC [3,4].